Display options
Cite
Vinik Y, Ortega FG, Mills GB, et al. Proteomic analysis of circulating extracellular vesicles identifies potential markers of breast cancer progression, recurrence, and response. Sci Adv. 2020;6(40)doi: 10.1126/sciadv.aba5714.
Vinik, Y., Ortega, F. G., Mills, G. B., Lu, Y., Jurkowicz, M., Halperin, S., Aharoni, M., Gutman, M., & Lev, S. (2020). Proteomic analysis of circulating extracellular vesicles identifies potential markers of breast cancer progression, recurrence, and response. Science advances, 6(40), . https://doi.org/10.1126/sciadv.aba5714
Vinik, Yaron, et al. "Proteomic analysis of circulating extracellular vesicles identifies potential markers of breast cancer progression, recurrence, and response." Science advances vol. 6,40 (2020). doi: https://doi.org/10.1126/sciadv.aba5714
Vinik Y, Ortega FG, Mills GB, Lu Y, Jurkowicz M, Halperin S, Aharoni M, Gutman M, Lev S. Proteomic analysis of circulating extracellular vesicles identifies potential markers of breast cancer progression, recurrence, and response. Sci Adv. 2020 Oct 02;6(40). doi: 10.1126/sciadv.aba5714. Print 2020 Oct. PMID: 33008904; PMCID: PMC7852393.
Copy Download .nbib Format: NLM
Share it on

Sci Adv. 2020 Oct 02;6(40). doi: 10.1126/sciadv.aba5714. Print 2020 Oct.

Proteomic analysis of circulating extracellular vesicles identifies potential markers of breast cancer progression, recurrence, and response.

Science advances

Yaron Vinik, Francisco Gabriel Ortega, Gordon B Mills, Yilling Lu, Menucha Jurkowicz, Sharon Halperin, Mor Aharoni, Mordechai Gutman, Sima Lev

Affiliations

  1. Weizmann Institute of Science, Rehovot, Israel.
  2. Knight Cancer Institute, Portland, OR 97201, USA.
  3. MD Anderson Cancer Center, Houston, TX 77030, USA.
  4. Sheba Medical Center, Tel-Hashomer, Israel.
  5. Weizmann Institute of Science, Rehovot, Israel. [email protected].

PMID: 33008904 PMCID: PMC7852393 DOI: 10.1126/sciadv.aba5714

Abstract

Proteomic profiling of circulating small extracellular vesicles (sEVs) represents a promising, noninvasive approach for early detection and therapeutic monitoring of breast cancer (BC). We describe a relatively low-cost, fast, and reliable method to isolate sEVs from plasma of BC patients and analyze their protein content by semiquantitative proteomics. sEV-enriched fractions were isolated from plasma of healthy controls and BC patients at different disease stages before and after surgery. Proteomic analysis of sEV-enriched fractions using reverse phase protein array revealed a signature of seven proteins that differentiated BC patients from healthy individuals, of which FAK and fibronectin displayed high diagnostic accuracy. The size of sEVs was significantly reduced in advanced disease stage, concomitant with a stage-specific protein signature. Furthermore, we observed protein-based distinct clusters of healthy controls, chemotherapy-treated and untreated postsurgery samples, as well as a predictor of high risk of cancer relapse, suggesting that the applied methods warrant development for advanced diagnostics.

Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).

References

  1. Arch Med Res. 2013 Apr;44(3):208-14 - PubMed
  2. Nat Rev Clin Oncol. 2018 Oct;15(10):617-638 - PubMed
  3. Indian J Surg Oncol. 2014 Mar;5(1):59-65 - PubMed
  4. Oncotarget. 2016 Jun 28;7(26):40189-40199 - PubMed
  5. Cancer Lett. 2010 Mar 28;289(2):127-39 - PubMed
  6. Cancer Lett. 2019 Sep 28;460:54-64 - PubMed
  7. Microarrays (Basel). 2015 Mar 24;4(2):98-114 - PubMed
  8. N Engl J Med. 2004 Dec 30;351(27):2817-26 - PubMed
  9. Am J Cancer Res. 2018 Jun 01;8(6):916-931 - PubMed
  10. Mol Cancer Ther. 2016 Nov;15(11):2598-2608 - PubMed
  11. BMC Med Inform Decis Mak. 2019 Mar 22;19(1):48 - PubMed
  12. Nature. 2018 Aug;560(7718):382-386 - PubMed
  13. N Engl J Med. 2018 Jul 12;379(2):111-121 - PubMed
  14. Commun Biol. 2019 Sep 3;2:325 - PubMed
  15. J Extracell Vesicles. 2016 Mar 24;5:29289 - PubMed
  16. Int J Mol Med. 2017 Sep;40(3):834-844 - PubMed
  17. Mol Cell Proteomics. 2014 Jul;13(7):1690-704 - PubMed
  18. Oncol Lett. 2016 Dec;12(6):4869-4876 - PubMed
  19. Breast Cancer Res. 2007;9(5):214 - PubMed
  20. Nat Rev Mol Cell Biol. 2018 Apr;19(4):213-228 - PubMed
  21. Proteomics. 2008 Aug;8(15):3051-60 - PubMed
  22. Contemp Oncol (Pozn). 2018 Mar;22(1A):38-40 - PubMed
  23. Oncotarget. 2017 Jun 20;8(25):41717-41733 - PubMed
  24. Curr Oncol. 2018 Jun;25(Suppl 1):S115-S124 - PubMed
  25. Radiat Oncol. 2019 May 10;14(1):78 - PubMed
  26. J Transl Med. 2018 Jan 9;16(1):1 - PubMed
  27. Nat Cell Biol. 2019 Feb;21(2):190-202 - PubMed
  28. Cell Mol Life Sci. 2018 Jan;75(2):193-208 - PubMed
  29. Cells. 2019 Sep 18;8(9): - PubMed
  30. Cancer Lett. 2012 Dec 31;327(1-2):142-52 - PubMed
  31. Oncotarget. 2017 Jan 31;8(5):7791-7800 - PubMed
  32. J Extracell Vesicles. 2017 Apr 10;6(1):1305677 - PubMed
  33. Breast Cancer Res Treat. 2019 Jun;175(2):339-351 - PubMed
  34. Anal Chem. 2017 Oct 17;89(20):11070-11075 - PubMed
  35. J Hematol Oncol. 2017 Dec 27;10(1):175 - PubMed
  36. Semin Oncol. 2016 Aug;43(4):476-83 - PubMed
  37. Protein Cell. 2016 Aug;7(8):548-61 - PubMed
  38. Pharmacogenomics J. 2010 Aug;10(4):292-309 - PubMed

Publication Types

Grant support